stocks logo

OBIO

Orchestra Biomed Holdings Inc
$
3.120
-0.04(-1.266%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.270
Open
3.160
VWAP
3.15
Vol
105.84K
Mkt Cap
119.54M
Low
3.080
Amount
333.75K
EV/EBITDA(TTM)
--
Total Shares
35.79M
EV
83.99M
EV/OCF(TTM)
--
P/S(TTM)
40.47
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
843.50K
+233.4%
--
--
742.33K
-24.79%
--
--
795.50K
+2.25%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Orchestra BioMed Holdings, Inc. (OBIO) for FY2025, with the revenue forecasts being adjusted by -24.83% over the past three months. During the same period, the stock price has changed by 13.45%.
Revenue Estimates for FY2025
Revise Downward
down Image
-24.83%
In Past 3 Month
Stock Price
Go Up
up Image
+13.45%
In Past 3 Month
4 Analyst Rating
up Image
308.65% Upside
Wall Street analysts forecast OBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OBIO is 12.75 USD with a low forecast of 12.00 USD and a high forecast of 15.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
up Image
308.65% Upside
Current: 3.120
sliders
Low
12.00
Averages
12.75
High
15.00
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$20
2025-04-22
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$14 → $12
2025-04-04
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$20
2025-04-01
Reason
BTIG
Marie Thibault
Strong Buy
Initiates
$12
2025-03-20
Reason
BTIG analyst Marie Thibault initiated coverage of Orchestra BioMed with a Buy rating and $12 price target. Orchestra is a medical technology company with a "unique business model maximizing its expertise in research and development while partnering with large companies to bring new devices to market, the analyst tells investors in a research note. The firm says the company's first two products are focused on the large, underserved markets of hypertension and coronary artery disease. While Orchestra is still proving out its business model, there is "plenty to like with the approach," contends BTIG.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$14
2025-03-10
Reason
Barclays
Matt Miksic
Buy
Initiates
$16
2025-01-02
Reason
Barclays initiated coverage of Orchestra BioMed with an Overweight rating and $16 price target. The firm sees a "series of catalysts" over the next 12-18 months for Orchestra which it expects to drive increasing interest and performance in the "innovative developer of high-impact medical devices." Orchestra Biomed's medical technology innovation and commercialization model focuses on developing high-impact medical device therapies through partnerships with large established medical device manufacturers, the analyst tells investors in a research note. Barclays says the company's pipeline of clinical programs represents an estimated total addressable markets of $14B.

Valuation Metrics

The current forward P/E ratio for Orchestra Biomed Holdings Inc (OBIO.O) is -1.58, compared to its 5-year average forward P/E of -2.74. For a more detailed relative valuation and DCF analysis to assess Orchestra Biomed Holdings Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.74
Current PE
-1.58
Overvalued PE
-0.14
Undervalued PE
-5.35

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.18
Current EV/EBITDA
-1.13
Overvalued EV/EBITDA
0.80
Undervalued EV/EBITDA
-3.15

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
56.12
Current PS
40.93
Overvalued PS
107.42
Undervalued PS
4.83

Financials

Annual
Quarterly
FY2025Q1
YoY :
+40.00%
868.00K
Total Revenue
FY2025Q1
YoY :
+31.19%
-18.92M
Operating Profit
FY2025Q1
YoY :
+39.31%
-18.76M
Net Income after Tax
FY2025Q1
YoY :
+28.95%
-0.49
EPS - Diluted
FY2025Q1
YoY :
+27.48%
-16.73M
Free Cash Flow
FY2025Q1
YoY :
+0.43%
94.93
Gross Profit Margin - %
FY2025Q1
YoY :
-5.87%
-1.91K
FCF Margin - %
FY2025Q1
YoY :
-0.49%
-2.16K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
8.2K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
225.6K
USD
8
Bought
0-3
0
0.0
USD
Months
3-6
2
275.7K
USD
Months
6-9
3
48.0K
USD
Months
0-12
3
62.5K
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 345.02% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
1
1.1M
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
238.2K
Volume
Months
0-12
1
3.0M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

OBIO News & Events

Events Timeline

2025-07-30 (ET)
2025-07-30
08:30:03
Nine new option listings on July 30th
select
2025-05-12 (ET)
2025-05-12
16:50:25
Orchestra BioMed reports Q1 EPS (49c), consensus (48c)
select
2025-05-07 (ET)
2025-05-07
08:33:11
Orchestra BioMed announces continued expansion of global property estate
select
Sign Up For More Events

News

9.0
06-24Newsfilter
Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe
9.0
06-18Newsfilter
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
4.0
05-13Benzinga
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Sign Up For More News

FAQ

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO) stock price today?

The current price of OBIO is 3.12 USD — it has decreased -1.27 % in the last trading day.

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO)'s business?

arrow icon

What is the price predicton of OBIO Stock?

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO)'s revenue for the last quarter?

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Orchestra Biomed Holdings Inc (OBIO)'s fundamentals?

arrow icon

How many employees does Orchestra Biomed Holdings Inc (OBIO). have?

arrow icon

What is Orchestra Biomed Holdings Inc (OBIO) market cap?